Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression

The original tricyclic antidepressant drugs are consistently underused in major depression because of side effects, delayed onset of action, and potential for overdose. In an open study of 6 weeks' duration, we studied the efficacy and acceptability of amineptine, a dopamine reuptake inhibitor, at fixed dose of 200 mg per day in 50 patients with major depression.Intention-to-treat analysis showed a patient response rate of 64% (95% CI 77-50) in HDRS, 62% (95% CI 75-48) in MADRS, 46% (95% CI 59-32) in ZUNG scale, 52% (95% CI 66-38) in Social Activity scale, and 26% ("95% CI 38-14) in CGI-severity of illness after 7 days treatment. Response in CGI-global improvement was 38% (95% CI 51-25), and in CGI-efficacy index 48% (95% CI 62-34) after 14 days of treatment. With continued therapy, only CGI-severity of illness showed a significant increase in response rate after 42 days. The treatment effect of amineptine was reflected in a significant and progressive improvement in all depression, social activity, and CGI rating scale scores throughout the study period. Somatic symptoms and side effects assessed by AMDP-5 showed significant improvement at each assessment.The clinically useful response in depression which occurred by the first week of treatment, favourable side effect profile, and the convenience of a fixed dose could make amineptine a suitable first line alternative for the treatment of major depression.